Ntiloudi Despoina, Kasinos Nearchos, Kalesi Alkistis, Vagenakis Georgios, Theodosis-Georgilas Anastasios, Rammos Spyridon
Department of Cardiology, Tzaneio General Hospital of Piraeus, 18536 Piraeus, Greece.
Echocardiography Training Center of Tzaneio 'D. Beldekos', 18536 Piraeus, Greece.
Diagnostics (Basel). 2024 Sep 16;14(18):2052. doi: 10.3390/diagnostics14182052.
Over the last decades, significant progress has been achieved in the pulmonary hypertension (PH) field. Pathophysiology of PH has been studied, leading to the classification of PH patients into five groups, while the hemodynamic definition has been recently revised. A diagnostic algorithm has been established and awareness has been raised in order to minimize diagnosis delay. The pulmonary arterial hypertension (PAH) treatment strategy includes the established three pathways of endothelin, nitric oxide-phosphodiesterase inhibitor, and prostacyclin pathway, but new therapeutic options are now being tested. The aim of this review is to summarize the existing practice and to highlight the novelties in the field of PH.
在过去几十年里,肺动脉高压(PH)领域取得了显著进展。人们对PH的病理生理学进行了研究,从而将PH患者分为五组,同时最近对血流动力学定义进行了修订。已建立了诊断算法,并提高了认知度,以尽量减少诊断延误。肺动脉高压(PAH)的治疗策略包括已确立的内皮素、一氧化氮-磷酸二酯酶抑制剂和前列环素三条途径,但目前正在测试新的治疗选择。本综述的目的是总结现有实践,并突出PH领域的新进展。